Showing results (11-20 of 329) with videos related to
Sort By:
Pageof 33
Current Cardiology Reports|June 21, 2020
Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?Michel R Langlois, Allan D SnidermanCurrent Atherosclerosis Reports|January 5, 2008
The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysisAllan D Sniderman, Robert S KissClinics in Laboratory Medicine|November 18, 2006
Apolipoprotein A1 and BAllan D Sniderman, Santica M MarcovinaCurrent Opinion in Lipidology|April 19, 2015
Limitations in the conventional assessment of the incremental value of predictors of cardiovascular riskAllan D Sniderman, Michael Pencina, George ThanassoulisJournal of the American College of Cardiology|March 11, 2022
Key Questions About Familial Hypercholesterolemia: JACC Review Topic of the WeekAllan D Sniderman, Tamara Glavinovic, George ThanassoulisJournal of the American College of Cardiology|March 18, 2014
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapiesAllan D Sniderman, Sotirios Tsimikas, Sergio FazioJournal of Lipid Research|January 3, 2004
ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytesMay Faraj, Allan D Sniderman, Katherine CianfloneThe Journal of Biological Chemistry|September 24, 2002
Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob miceZhunan Xia, Allan D Sniderman, Katherine CianfloneJAMA Cardiology|November 14, 2018
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary PreventionGeorge Thanassoulis, Allan D Sniderman, Michael J PencinaCurrent Opinion in Lipidology|September 29, 2023
Triglyceride-rich lipoprotein cholesterol and cardiovascular riskSelin Bilgic, Alan T Remaley, Allan D SnidermanPageof 33